Drug intelligence / Profile preview

LIBP-Rec-Vaccine

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

LIBP-Rec-Vaccine is a recombinant COVID-19 vaccine developed for intramuscular administration, currently being evaluated in a randomized, double-blind, placebo-controlled Phase III clinical trial. The vaccine is designed to induce an immune response against SARS-CoV-2 and is administered as a booster dose to individuals previously vaccinated with either inactivated or mRNA COVID-19 vaccines. The mechanism of action involves stimulating the immune system to recognize and respond to the SARS-CoV-2 virus through recombinant protein technology[1].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on LIBP-Rec-Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIBP-Rec-Vaccine.

Explore the full profile